The Food and Drug Administration (FDA) has approved an additional indication for Jardiance (empagliflozin; Boehringer Ingelheim and Lilly) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease.
The American Academy of Pediatrics has endorsed new guidelines recommending the screening of all obese children aged 9 to 11 for non-alcoholic fatty liver disease (NAFLD).
A new vaccine has shown potential to effectively suppress the addiction liability and overdose potential of prescription opioids; oxycodone (oxy) and hydrocodone (hydro).
To address the lack of standardized management guidelines in the treatment of psoriasis, the National Psoriasis Foundation conducted a study among psoriasis experts in an effort to define consensus based treatment targets.
Aradigm has announced top-line results from two Phase 3 clinical trials of Pulmaquin (inhaled ciprofloxacin) for the treatment of patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic lung infections with Pseudomonas aeruginosa.